News

The MAA is proudly celebrating ten years with all our keen supporters by sharing a few words from the three founding members who have been an integral part of this wonderful decade of the alliance.

Please do view the timeline included here. It reflects the key components of our history. We are sure that you will find the variety of content inspiring and diverse. 

Thank you to all our MG Community for their continued support. 

Together we are a strong and influencing voice!

The MAA asks – “Do you receive regular IVIg?” If so, this consumer engagement opportunity may be important to you. 

Please consider if you would like to have your say on the following scenario. Participants need to register prior to Monday October 21st to ensure a place. 

The MAA respectfully requests patient support in further telling the story of their experiences with all forms of Myasthenia. Please note, we are very pleased that this survey can be completed via a hardcopy option. Please call Libby on 0407 110 204 to arrange this.

We are very sorry but the planned MAA PBAC Update webinar, scheduled for Friday 11 October 2024, is postponed until further notice.

Please keep an eye on our emails, website, and social media to ensure you stay updated.

The Myasthenia Alliance Australia (MAA) Board invite the Myasthenia community of Australia to join the following webinar. 

The Board thanks Alexion for facilitating this opportunity to understand more about the processes involved in achieving new treatment options.

You are invited to a Zoom webinar on Friday 11 October at 12pm (daylight saving time) to hear from the Alexion team about the recent Pharmaceutical Benefits Advisory Committee (PBAC) Submission outcome and to learn a bit more about the process itself.

Recently the Pharmaceutical Benefits Advisory Committee (PBAC) announced the outcome of their July Meeting. The MG community were keenly waiting to hear the PBAC Outcomes as two new medications, Raviluzimab and Zilucoplan, had been reviewed. Regrettably both medications received a ”Not Recommended” verdict. The PBAC did recognise the high clinical need for effective therapies for gMG. 

Our MessaGes' August Newsletter is now published.

 Click here to read it!  

At the close of nominations for the MGAQ Management Committee, there were still THREE VACANT POSITIONS.  To meet our legislative requirements, we MUST HAVE A SECRETARY.  Also, two more management committee members are required.   

The Myasthenia Alliance Australia (MAA) supports and promotes research that is specific to the experience of Myasthenia Gravis (MG) patients in Australia. But we would not be able to do this without the essential and valuable contribution of Australians with MG.

To Australians with Myasthenia, the following is a message from Dr Carolina Barnette-Tapia MD, PhD of Canada.

The MAA thank Australians for their interest in supporting this project. Responses will be welcomed until early September 2024. Information about the outcomes resulting from this research has been requested.

Disclosure information is provided after logging in.